包装: | 1mg |
规格: | 98% |
市场价: | 9261元 |
分子量: | 725.79 |
Background:
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.
SGD-1882 is the cytotoxic payload undergoing clinical evaluation for anti-CD33 and anti-CD70 conjugates[1]. SGD-1882 is not an MDR1 substrate, and SGN-CD33A is conjugated to the SGD-1882. SGN-CD33A can kill MDR1 expressing CD33 positive AML patient samples and is currently in Phase I[2].
[1]. Eunhee G. Kim, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015 Nov; 23(6): 493-509.
[2]. Dowdy Jackson, et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res. 2015; 32(11): 3458-3469.
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |